01.17.20
Nanoform, an innovative nanoparticle medicine enabling company, has appointed Sally Langa as head of U.S. sales. The new role will enable Nanoform to continue its growth with a strengthened presence in the U.S. market.
As head of U.S. sales, Ms. Langa will drive business development in this key region. Together with the rest of the commercial team, she will introduce and accelerate growth of Nanoform’s technology platform to major pharma and biotech companies in the U.S. market.
Ms. Langa has more than 30 years experience and a successful track record in senior business development positions in the field of formulations, tackling poorly soluble drugs. She has previously worked as vice president, global business development, development and analytical services for Catalent, and has also held other senior roles at Halo Pharmaceutical and Patheon.
The appointment comes at a time of growth for Nanoform, which recently filed for GMP status with the Finnish Medicines Agency, FIMEA. This increased manufacturing capability combined with the strengthening of its international commercial organization will enable the company to extend the reach of its award-winning nanonization technology.
“I am delighted to welcome Sally Langa to Nanoform,” said Edward Hæggström, chief executive officer, Nanoform. “The U.S. market is the largest in the world, and with this key appointment, we are now well positioned to build upon our current traction in this region.”
Christian Jones, chief commercial officer, said, “It is fantastic to have Sally join the commercial team. We have seen strong interest from the U.S. market and this appointment is key in driving further growth and ensuring our technology is as widely adopted as possible by our current and future partners. I look forward to working with a fellow professional with exceptional expertise in business development and in-depth knowledge of formulation enhancement.”
As head of U.S. sales, Ms. Langa will drive business development in this key region. Together with the rest of the commercial team, she will introduce and accelerate growth of Nanoform’s technology platform to major pharma and biotech companies in the U.S. market.
Ms. Langa has more than 30 years experience and a successful track record in senior business development positions in the field of formulations, tackling poorly soluble drugs. She has previously worked as vice president, global business development, development and analytical services for Catalent, and has also held other senior roles at Halo Pharmaceutical and Patheon.
The appointment comes at a time of growth for Nanoform, which recently filed for GMP status with the Finnish Medicines Agency, FIMEA. This increased manufacturing capability combined with the strengthening of its international commercial organization will enable the company to extend the reach of its award-winning nanonization technology.
“I am delighted to welcome Sally Langa to Nanoform,” said Edward Hæggström, chief executive officer, Nanoform. “The U.S. market is the largest in the world, and with this key appointment, we are now well positioned to build upon our current traction in this region.”
Christian Jones, chief commercial officer, said, “It is fantastic to have Sally join the commercial team. We have seen strong interest from the U.S. market and this appointment is key in driving further growth and ensuring our technology is as widely adopted as possible by our current and future partners. I look forward to working with a fellow professional with exceptional expertise in business development and in-depth knowledge of formulation enhancement.”
